Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device-Based Stroke Intervention: An Interview with Adnan Siddiqui

Executive Summary

Medtech Insight interviews Adnan Siddiqui, MD, PhD, assistant professor of neurosurgery and radiology at the State University of New York, Buffalo, a pioneer in the use of interventional technology for acute ischemic stroke. Siddiqui offers his perspective on the current state of endovascular devices for AIS, the unique challenges faced by physicians in this field, and the factors driving interest in stent-based technologies.

You may also be interested in...



Stroke Devices: Innovation Drives Growth

Innovation is driving double-digit growth in the neurointerventional device market as an increasing number of medical device manufacturers develop newer, more effective devices for treating acute ischemic stroke. As new, stent-like retrieval systems and other next-generation neurothrombectomy devices hit the US market in the next few years, competition in this sector will also heat up as manufacturers try to differentiate their devices and jockey for a piece of the market, which is projected to reach almost $70 million by 2015.

Stroke Devices: Innovation Drives Growth

Innovation is driving double-digit growth in the neurointerventional device market as an increasing number of medical device manufacturers develop newer, more effective devices for treating acute ischemic stroke. As new, stent-like retrieval systems and other next-generation neurothrombectomy devices hit the US market in the next few years, competition in this sector will also heat up as manufacturers try to differentiate their devices and jockey for a piece of the market, which is projected to reach almost $70 million by 2015.

The Neurovascular Market Tilts Toward A Tipping Point

Acute ischemic stroke used to be a device category that promised a slow but certain death for start-ups. But there's lots of life in the market, as evidenced by a recent wave of consolidation. Meanwhile, hemorrhagic stroke companies have been perfecting the treatment of cerebral aneurysms.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT035345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel